- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Tusk Therapeutics Ltd.
Headquarters: Stevenage, United Kingdom
Website: N/A
Year Founded: 2015
Status: Acquired
BioCentury | May 11, 2021
Finance
Droia parlays cancer fund success into genetic disease-themed vehicle as Golumbeski joins as partner
Firm expands into genetic diseases with €220M fund
BioCentury | Aug 15, 2020
Management Tracks
Myriad chooses Diaz as new CEO; plus changes at Novocure, Werewolf, Jasper, Avacta, Tarsus and more
Former Kindred Healthcare CEO Paul Diaz has become president and CEO of Myriad Genetics Inc. (NASDAQ:MYGN). He replaces Mark Capone, who left the molecular diagnostics company in February after
BioCentury | Mar 28, 2020
Management Tracks
Bernard joins Qiagen as CEO; plus CytomX, Recursion, 89bio, Heptares, Fusion, Freeline, Cognition, I-Mab, Seres and more
BioCentury | Jan 11, 2020
Finance
Why buysiders say 2020 could be the year of the CNS
Neurology is back, as buysiders home in on 2020 opportunities
BioCentury | Dec 9, 2019
Company News
Sanofi broadens oncology capabilities, adds IL-2 program via $2.5B Synthorx takeout
BioCentury | Oct 19, 2018
Company News
SQZ, Roche expand deal to jointly develop cancer cell therapies
BioCentury | Oct 15, 2018
Company News
SQZ, Roche expand deal to jointly develop cancer cell therapies
BioCentury | Jun 21, 2018
Product R&D
Tusk’s take on CD25
How Tusk is bringing CD25 mAbs back into cancer
Items per page:
1 - 10 of 13